Amgen opens $365m Ohio drug product facility

Amgen has opened a nearly 300,000 square-foot biomanufacturing plant in New Albany, Ohio.

Shreeyashi Ojha, Reporter

March 6, 2024

1 Min Read
c/o Amgen

Announced in June 2022, and confirmed in November 2022, the firm has spent $365 million on the expansion of its drug product facility to support assembly and packaging for its medicines.  

According to the firm, the 270,000 square-foot facility will create 400 jobs and will adhere to Amgen’s commitment to achieve carbon neutrality for all operations by 2027.   

“Our Ohio site is Amgen’s digitally advanced final product assembly and packaging facility, leveraging the latest innovations in manufacturing to improve safety and efficiency,” a spokesperson for Amgen told BioProcess Insider. 

“Amgen built the facility to provide additional capacity to support the growing demand for Amgen medicines in the US market. This new advanced final product assembly and packaging plant will increase Amgen’s manufacturing network capacity, enabling Amgen to reliably supply more medicines for patients.” 

According to the firm, the plant is designed to assemble, label and package vials and syringes for a wide variety of Amgen medicines. Furthermore, it will feature assembly and final product packaging capabilities based on advanced digital automation technologies, though specifics were not divulged. 

The spokesperson added, “We do not comment on what specific medicines are made at each facility. We invested $474 million into the Ohio site, which was within our expected range and the project was completed ahead of schedule.” 

For the full year 2023, Amgen reported a 20% increase revenue year-on-year, corresponding to $8.2 billion. Moreover, Amgen anticipates up to a dozen significant pipeline milestones in 2024. “2023 was another year of performance and progress for our company," said Robert Bradway, CEO of Amgen said during the firm’s financial call last month.

“Our marketed products are reaching many more patients around the world, and we anticipate more than a dozen significant pipeline milestones in 2024.”

About the Author(s)

Shreeyashi Ojha

Reporter, BioProcess Insider

Journalist covering the manufacturing and processing sectors for biopharmaceuticals globally.  

Originally from India, I am a Londoner at heart. I have recently graduated from Goldsmiths, University of London.  

Feel free to reach out to me at: [email protected].

You May Also Like